Association of Serum FAM19A5 with Cognitive Impairment in Vascular Dementia

作者：Juan Li, Shoulin Li, Yihong Song, Wei Zhou, Xiaohao Zhu, Suo Xu, Yihong Ma, Chunlin Zhu · 发表于：Disease Markers · 年份：2020 · DOI：10.1155/2020/8895900 · 被引用次数：21 · 研究领域：Neurological Disease Mechanisms and Treatments、GDF15 and Related Biomarkers、Neuroinflammation and Neurodegeneration Mechanisms

Objective . Family with sequence similarity 19 member A5 (FAM19A5), a novel chemokine-like peptide, is a secreted protein mainly expressed in the brain. FAM19A5 was recently found to be involved in a variety of neurological diseases; however, its correlation with vascular dementia (VaD) remains unclear. The aim of the study is to explore the association between serum FAM19A5 and cognitive impairment in subjects with VaD. Method . 136 VaD subjects and 81 normal controls were recruited in the study. Their demographic and clinical baseline data were collected on admission. All subjects received Mini-Mental State Examination (MMSE) evaluation, which was used to test their cognitive functions. A sandwich enzyme-linked immunosorbent assay (ELISA) was applied to detect the serum levels of FAM19A5. Results . No significant differences were found between the two groups regarding the demographic and clinical baseline data ( p > 0.05 ). The serum FAM19A5 levels were significantly higher compared to normal controls ( p < 0.001 ). The Spearman correlation analysis indicated that serum FAM19A5 levels and MMSE scores have a significant negative correlation in VaD patients ( r = − 0.414 , <0.001). Further multiple regression analysis indicated that serum FAM19A5 levels were independent risk predictors for cognitive functions in VaD ( β = 0.419 , p = 0.031 ). Conclusion . The serum FAM19A5 level of VaD patients is significantly increased, which may serve as a bi...